Petar Jelinic

2.5k total citations
30 papers, 1.2k citations indexed

About

Petar Jelinic is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Petar Jelinic has authored 30 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 14 papers in Oncology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Petar Jelinic's work include Chromatin Remodeling and Cancer (7 papers), Cancer Mechanisms and Therapy (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Petar Jelinic is often cited by papers focused on Chromatin Remodeling and Cancer (7 papers), Cancer Mechanisms and Therapy (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Petar Jelinic collaborates with scholars based in United States, Japan and Spain. Petar Jelinic's co-authors include Phillip Shaw, Douglas A. Levine, Narciso Olvera, Robert A. Soslow, Jennifer J. Mueller, Fanny Dao, Gregory David, Mithat Gönen, Sasinya N. Scott and Ronak Shah and has published in prestigious journals such as Nature Communications, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Petar Jelinic

29 papers receiving 1.2k citations

Peers

Petar Jelinic
Jeffrey R. Haswell United States
Kirsten Kübler Germany
Michela Visani Italy
Kiyomi O. Toyooka United States
Dominiek Smeets Belgium
Mark E. Borowsky United States
Atsuko Katagiri Japan
Selina Glaros United States
Musaffe Tuna United States
Guangwu Zhu United States
Jeffrey R. Haswell United States
Petar Jelinic
Citations per year, relative to Petar Jelinic Petar Jelinic (= 1×) peers Jeffrey R. Haswell

Countries citing papers authored by Petar Jelinic

Since Specialization
Citations

This map shows the geographic impact of Petar Jelinic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petar Jelinic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petar Jelinic more than expected).

Fields of papers citing papers by Petar Jelinic

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Petar Jelinic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petar Jelinic. The network helps show where Petar Jelinic may publish in the future.

Co-authorship network of co-authors of Petar Jelinic

This figure shows the co-authorship network connecting the top 25 collaborators of Petar Jelinic. A scholar is included among the top collaborators of Petar Jelinic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Petar Jelinic. Petar Jelinic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Makker, Vicky, Matthew H. Taylor, Carol Aghajanian, et al.. (2024). Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146. Journal for ImmunoTherapy of Cancer. 12(1). e007929–e007929. 5 indexed citations
2.
3.
Makker, Vicky, Matthew H. Taylor, Carol Aghajanian, et al.. (2021). 796P Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111. Annals of Oncology. 32. S760–S760. 1 indexed citations
4.
Ledermann, Jonathan A., Ronnie Shapira‐Frommer, Alessandro D. Santin, et al.. (2020). 843P Association of gene expression signatures and TMB with response to pembrolizumab (pembro) in patients (pts) with recurrent ovarian cancer (ROC) enrolled in KEYNOTE-100. Annals of Oncology. 31. S631–S632. 2 indexed citations
5.
Osmanbeyoglu, Hatice U., Fumiko Shimizu, Ángela Rynne‐Vidal, et al.. (2019). Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers. Nature Communications. 10(1). 4369–4369. 18 indexed citations
6.
Jelinic, Petar, et al.. (2019). Mechanisms of SWI/SNF dysfunction in the immune-reactive microenvironment of small cell carcinoma of the ovary, hypercalcemic type. Gynecologic Oncology. 154. 32–32. 1 indexed citations
7.
Mısırlıoğlu, Selim, et al.. (2019). Abstract 531: The cGAS-STING pathway as a driver of the immune-reactive microenvironment in small cell carcinoma of the ovary, hypercalcemic type. Cancer Research. 79(13_Supplement). 531–531. 1 indexed citations
8.
Fehniger, Julia, et al.. (2018). Small cell cancers of the female genital tract: Molecular and clinical aspects. Gynecologic Oncology. 149(2). 420–427. 38 indexed citations
9.
Tseng, Jill, Maria Bisogna, Lien Hoang, et al.. (2017). miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. Scientific Reports. 7(1). 3614–3614. 22 indexed citations
10.
Jelinic, Petar, Brooke A. Schlappe, Niamh Conlon, et al.. (2015). Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type. Modern Pathology. 29(1). 60–66. 50 indexed citations
11.
Conlon, Niamh, Annacarolina da Silva, Esther Guerra, et al.. (2015). Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type. The American Journal of Surgical Pathology. 40(3). 395–403. 73 indexed citations
12.
Broach, Vance, Brooke A. Schlappe, Faina Bogomolniy, et al.. (2015). Tumor-derived serum exosomal microRNA as a novel biomarker for high-grade serous carcinoma. Gynecologic Oncology. 137. 13–13. 1 indexed citations
13.
Jelinic, Petar & Douglas A. Levine. (2014). New Insights into PARP Inhibitors' Effect on Cell Cycle and Homology-Directed DNA Damage Repair. Molecular Cancer Therapeutics. 13(6). 1645–1654. 65 indexed citations
14.
Jelinic, Petar, Jennifer J. Mueller, Narciso Olvera, et al.. (2014). Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nature Genetics. 46(5). 424–426. 266 indexed citations
15.
Jelinic, Petar & Douglas A. Levine. (2014). Abstract 4550: Differential PARP inhibitors' effects on cell cycle and consequently homologous DNA damage repair. Cancer Research. 74(19_Supplement). 4550–4550. 1 indexed citations
16.
Barlin, Joyce N., Petar Jelinic, Narciso Olvera, et al.. (2012). Validated gene targets associated with curatively treated advanced serous ovarian carcinoma. Gynecologic Oncology. 128(3). 512–517. 42 indexed citations
17.
18.
Grandinetti, Kathryn B., Petar Jelinic, Rachel Ruoff, et al.. (2009). Sin3B Expression Is Required for Cellular Senescence and Is Up-regulated upon Oncogenic Stress. Cancer Research. 69(16). 6430–6437. 45 indexed citations
19.
Jelinic, Petar & Phillip Shaw. (2006). Loss of imprinting and cancer. The Journal of Pathology. 211(3). 261–268. 170 indexed citations
20.
Jelinic, Petar, et al.. (2006). The Testis-Specific Factor CTCFL Cooperates with the Protein Methyltransferase PRMT7 in H19 Imprinting Control Region Methylation. PLoS Biology. 4(11). e355–e355. 155 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeffrey R. Haswell Breakdown of academic impact, for papers by Kirsten Kübler Breakdown of academic impact, for papers by Michela Visani Breakdown of academic impact, for papers by Kiyomi O. Toyooka Breakdown of academic impact, for papers by Dominiek Smeets Breakdown of academic impact, for papers by Mark E. Borowsky Breakdown of academic impact, for papers by Atsuko Katagiri Breakdown of academic impact, for papers by Selina Glaros Breakdown of academic impact, for papers by Musaffe Tuna Breakdown of academic impact, for papers by Guangwu Zhu
Rankless by CCL
2026